SCHEMBL1367660

SCHEMBL1367660

CCOc1cccc2cc(C(=O)CC(=O)C=Cc3ccc(OC)cc3)c(=O)sc12

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.49
MAOA P21397 1/20 0.49
MAPT P10636 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
PLIN1 O60240 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
RAB9A P51151 1/20 0.46
PLIN5 Q00G26 1/20 0.46
ABHD5 Q8WTS1 1/20 0.46
TOP2A P11388 2/20 0.44
MAOB P27338 2/20 0.43
PADI4 Q9UM07 1/20 0.42
BACE1 P56817 2/20 0.41
APP P05067 1/20 0.41
CLK1 P49759 1/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367659 1.00 GSK3B (0.49) GSK3BMAOAMAPTMEN1KMT2A
SCHEMBL1369133 1.00 GSK3B (0.49) GSK3BMAOAMAPTMEN1KMT2A
SCHEMBL829624 0.83 MAOA (0.45) GSK3BMAOAMAPTMEN1KMT2A
SCHEMBL829625 0.83 MAOA (0.45) GSK3BMAOAMAPTMEN1KMT2A
SCHEMBL830747 0.83 MAOA (0.45) GSK3BMAOAMAPTMEN1KMT2A
SCHEMBL1365955 0.82 MAOA (0.65) GSK3BMAOAMAPTMEN1KMT2A
SCHEMBL1366951 0.82 MAOA (0.65) GSK3BMAOAMAPTMEN1KMT2A
SCHEMBL1365956 0.82 MAOA (0.65) GSK3BMAOAMAPTMEN1KMT2A
SCHEMBL1368844 0.81 CHRNA7 (0.45) MEN1KMT2AALDH1A1RAB9A
SCHEMBL1369151 0.80 GSK3B (0.52) GSK3BMAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS GSK3B 4183/4885MAOA 3570/4885MAPT 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.